Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer. This rapid genomic tumor profiling test, previously known as PCDx, allows physicians to understand patients’ tumor profiles and effectively recommend targeted therapies or clinical trials based on the biology of their patients’ cancers. He also talks about the broader Oncology Business Unit at Exact Sciences.
Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop and commercialize the Oncotype DX® breast cancer, colon cancer, prostate cancer and liquid biopsy assays.
Dr. Baehner is also a faculty member at the University of California, San Francisco and has been a leader in breast pathology and cytopathology for more than a decade.